Literature DB >> 30466190

Outcome after reconstruction of proximal femoral tumors: A systematic review.

Stein J Janssen1, David W G Langerhuizen2, Joseph H Schwab3, Jos A M Bramer2.   

Abstract

Tumor resection followed by reconstruction with a proximal femoral endoprosthesis or an allograft-prosthesis composite are the two main alternatives for treatment of proximal femoral malignancies. This review describes the revision rate, implant survival, limb salvage rate, and function. Overall revision rates are high and reasons for failure differ between treatment modalities. Rate and reasons for amputation are comparable between both methods. Functional outcome was reasonable to good on average for both treatment modalities. Level of evidence: IV, systematic review and meta-analysis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  allograft; benign; cancer; femoral; femur; malignant; prosthesis; proximal; reconstruction; replacement; tumor

Mesh：

Year:  2018        PMID： 30466190     DOI： 10.1002/jso.25297

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  11 in total

1.  CORR Insights®: Causes and Frequencies of Reoperations After Endoprosthetic Reconstructions for Extremity Tumor Surgery: A Systematic Review.

Authors:  Stein J Janssen
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

2.  Comparable outcomes of recycled autografts and allografts for reconstructions in patients with high-grade osteosarcoma.

Authors:  Kuan-Lin Chen; Chao-Ming Chen; Cheng-Fong Chen; Yu-Chi Cheng; Yu-Kuan Lin; Shang-Wen Tsai; Tain-Hsiung Chen; Po-Kuei Wu; Wei-Ming Chen
Journal:  Int Orthop       Date:  2021-08-19       Impact factor: 3.075

Review 3.  Proximal femur versus acetabular extra-articular resection of the hip joint for primary malignant bone tumors: a retrospective comparative review of 33 cases.

Authors:  Victor Housset; Philippe Anract; Antoine Babinet; Guillaume Auberger; David Biau
Journal:  World J Surg Oncol       Date:  2022-05-28       Impact factor: 3.253

Review 4.  Limb Salvage and Reconstruction Options in Osteosarcoma.

Authors:  Samuel Z Grinberg; Abigail Posta; Kristy L Weber; Robert J Wilson
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Salvage Reconstruction With the Masquelet Technique Following Wide Resection for Chondrosarcoma of the Proximal Femoral Metaphysis: A Case Report.

Authors:  Michiyuki Hakozaki; Ryoichi Kawakami; Nobuyuki Sasaki; Narihiro Toshiki; Yoichi Kaneuchi; Hitoshi Yamada; Shinichi Konno
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

6.  Survival and outcomes of modular endoprosthetic reconstruction of the proximal femur for primary and non-primary bone tumors: Single institutional results.

Authors:  Charles A Gusho; Bishir Clayton; Nabil Mehta; Matthew W Colman; Steven Gitelis; Alan T Blank
Journal:  J Orthop       Date:  2021-05-07

Review 7.  Strategies for managing the destruction of calcar femorale.

Authors:  Jin Mei; Lili Pang; Zhongchao Jiang
Journal:  BMC Musculoskelet Disord       Date:  2021-05-19       Impact factor: 2.362

8.  Compliant Compression Reconstruction of the Proximal Femur Is Durable Despite Minimal Bone Formation in the Compression Segment.

Authors:  Alexander B Christ; Tomohiro Fujiwara; Nicola Fabbri; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2021-07-01       Impact factor: 4.755

9.  "Purse-String" Capsular Closure for Decreasing Dislocation Rates in Proximal Femur Replacements.

Authors:  Thomas A Novack; Jay N Patel; Tyler Hoskins; Charles Long; Christopher Mazzei; David Goyette; James C Wittig
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2020-11-10

10.  Long-term results of uncemented allograft prosthesis composite reconstruction for the tumor in proximal femur: a minimum follow-up of sixty-five months.

Authors:  Cai Liu; Li Min; Yong Zhou; Yi Luo; Fan Tang; Minxun Lu; Hong Duan; Wenli Zhang; Xinzhu Yu; Chongqi Tu
Journal:  BMC Musculoskelet Disord       Date:  2021-02-01       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.